

# **RESPONDING TO CHILDREN AND ADOLESCENTS WHO HAVE BEEN SEXUALLY ABUSED**

---

WHO CLINICAL GUIDELINES



**World Health  
Organization**



# **RESPONDING TO CHILDREN AND ADOLESCENTS WHO HAVE BEEN SEXUALLY ABUSED**

---

WHO CLINICAL GUIDELINES



**World Health  
Organization**

Responding to children and adolescents who have been sexually abused: WHO clinical guidelines

ISBN 978-92-4-155014-7

© **World Health Organization 2017**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Responding to children and adolescents who have been sexually abused: WHO clinical guidelines. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

# Contents

<b>Acknowledgements</b>	<b>v</b>
<b>Acronyms and abbreviations</b>	<b>vi</b>
<b>Glossary</b>	<b>vii</b>
<b>Executive summary</b>	<b>1</b>
<b>Summary of guiding principles</b>	<b>2</b>
<b>Summary of recommendations (R) and good practice statements (GP)</b>	<b>2</b>
<b>1. Background</b>	<b>7</b>
A. The magnitude of child and adolescent sexual abuse	7
B. Health consequences of child and adolescent sexual abuse	7
C. Use of health services by children and adolescents who have experienced sexual abuse	8
D. Objectives of and rationale for this guideline	8
E. Target audience	9
F. Scope of the guideline	10
<b>2. Methods</b>	<b>11</b>
A. Guideline contributors	11
B. Declaration of interests by external contributors	11
C. Identification of priority research questions and outcomes – scoping exercise	12
D. Values and preferences to inform good practices and guiding principles	12
E. Evidence retrieval	13
F. Quality assessment, synthesis and grading of the evidence	13
G. Formulation of recommendations	13
H. Document preparation and peer-review	14
<b>3. Guiding principles derived from ethical principles and human rights standards</b>	<b>15</b>
A. The principle of best interests of the child or adolescent	15
B. The principle of evolving capacities of the child or adolescent	16
C. The principle of non-discrimination	17
D. The principle of participation	17
<b>4. Recommendations and good practice statements</b>	<b>18</b>
A. Child- or adolescent-centred care/first-line support	18
B. Medical history, physical examination and documentation of findings	20

C.	HIV post-exposure prophylaxis treatment and adherence	23
D.	Pregnancy prevention and management among girls who have been sexually abused	28
E.	Post-exposure prophylaxis for curable and vaccine-preventable sexually transmitted infections	29
F.	Psychological and mental health interventions in the short term and longer term	33
G.	Ethical principles and human rights standards for reporting child or adolescent sexual abuse	38
<b>5.</b>	<b>Implementation considerations</b>	<b>43</b>
A.	Facilitating timely uptake of services	43
B.	Creating a supportive and enabling service-delivery environment for health-care providers	44
<b>6.</b>	<b>Research implications</b>	<b>46</b>
A.	Child- or adolescent-centred care/first-line support	46
B.	Medical history, physical examination and documentation of findings	46
C.	HIV post-exposure prophylaxis treatment and adherence	46
D.	Post-exposure prophylaxis for curable and vaccine-preventable sexually transmitted infections	47
E.	Psychological and mental health interventions in the short term and longer term	47
F.	Ethical principles and human rights standards for reporting child or adolescent sexual abuse	47
G.	Implementation considerations	47
<b>7.</b>	<b>Dissemination, implementation, monitoring and evaluation</b>	<b>49</b>
<b>8.</b>	<b>Updating the guideline</b>	<b>51</b>
	<b>References</b>	<b>52</b>
	<b>Annex 1. Guideline contributors</b>	<b>67</b>
	WHO Steering Group	67
	Guideline Development Group	68
	External Review Group	70
	<b>Annex 2. Implications of the strength of the recommendation</b>	<b>71</b>
	<b>Annex 3. International and regional human rights treaties and consensus documents containing safeguards that are relevant for child and adolescent sexual abuse</b>	<b>72</b>
	<b>Annex 4. List of supplementary materials in Web Annexes</b>	<b>74</b>

# Acknowledgements

The Department of Reproductive Health and Research (RHR), at the World Health Organization (WHO), has produced this guideline document, under the leadership of Claudia Garcia-Moreno. Avni Amin (responsible technical officer) and Megin Reijnders coordinated the development of this guideline. The WHO Steering Group (Avni Amin, Alexander Butchart, V Chandra-Mouli, Nathan Ford, Mary Lynn Gaffield, Claudia Garcia-Moreno, Rajat Khosla, Berit Kieselbach, Christopher Mikton, Martina Penazzato, Megin Reijnders, David Ross, Chiara Servili, Satvinder Singh, Mark Van Ommeren and Teodora Wi) gratefully acknowledges the contributions of all the Guideline Development Group (GDG) members: Maha Almuneef, Sialondwe Mujimba Derrick, Lina Akinyi Digolo, Asvini Fernando, Maria Herczog, Christopher Hobbs, Virginia Francis Iliff, Elizabeth J Letourneau, Harriet MacMillan (Co-Chair), Bernadette J Madrid (Co-Chair), Ben Mathews, Neil McKerrow, Pratima Mittal, Asha Pemberton-Gaskin and Meggy Verputten. We also acknowledge the guidance of Cicely Marston as the GRADE Methodologist.

RHR also thanks the following individuals, who participated in the GDG meeting as observers: Jessie Gleckel (United States Centers for Disease Control and Prevention [CDC]), Rebecca Gordon (Together for Girls) and Amelia Peltz (United States Agency for International Development [USAID]) and the following external contributors who peer-reviewed the guideline: Christine Amisi, Irene Guat Sim Cheah, Vikas Choudhry, Aaron Miller, Emily Monaghan, Ana Maria Aguirre Monteverde and Richard Roylance.

A special thanks to the systematic review teams: Kerry Scott (Lead), Elena Broaddeus and Sara Beckham (qualitative reviews for the good practices related to first-line support; medical history, examination, documentation, facilitating uptake of services and creating enabling service-delivery environment); Zara Shubber (Lead) and Nathan Ford (HIV PEP adherence systematic review); Philippe Mayaud (Lead) and Helen Kelly (STI prevention and treatment); Jill McTavish (Lead), Donna Fitzpatrick and Ali Usman (psychological interventions); and Ben Mathews (Lead) and Juliet Davis (good practice related to reporting of child sexual abuse).

The guideline was written by Avni Amin, Megin Reijnders and Susanne Carai and reviewed by Claudia Garcia-Moreno.

The WHO Steering Group would like to thank the WHO Guidelines Review Committee Secretariat for their overall support during the guideline development process, with particular thanks to Susan L Norris.

We appreciate the contributions of the following individuals to the development of this guideline: Penny Howes (editor), Sue Hobbs (design and layout), Philippa May (proof reader).

The development of this guideline was funded by: a grant from the United States Government's President's Emergency Plan For AIDS Relief (PEPFAR); and the United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/United Nations Children's Fund (UNICEF)/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP).

# Acronyms and abbreviations

ARV	antiretroviral drug
CBT	cognitive behavioural therapy
CEDAW	Convention on the Elimination of all Forms of Discrimination against Women
CDC	Centers for Disease Control and Prevention (United States of America)
COC	combined oral contraceptive
CRC	Convention on the Rights of the Child
Cu-IUD	copper-bearing intrauterine device
ECP	emergency contraceptive pill
EMDR	eye movement desensitization and reprocessing
ERG	External Review Group
GDG	Guideline Development Group
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
HIV	human immunodeficiency virus
HPV	human papillomavirus
IPT	interpersonal psychotherapy
LGBTI	lesbian, gay, bisexual, transgender and intersex
LMIC	low- and middle- income country
LNG	levonorgestrel
mHealth	mobile health
mhGAP	WHO Mental Health Gap Action Programme
NAAT	nucleic acid amplification test
PEP	post-exposure prophylaxis (for HIV)
PICO	population, intervention, comparator, outcome
PTSD	post-traumatic stress disorder
SIT	stress inoculation training

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26206](https://www.yunbaogao.cn/report/index/report?reportId=5_26206)

